-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Propagermanium in Chronic Kidney Disease (Chronic Renal Failure)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Propagermanium in Chronic Kidney Disease (Chronic Renal Failure) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Propagermanium in Chronic Kidney Disease (Chronic Renal Failure)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Baxdrostat in Chronic Kidney Disease (Chronic Renal Failure)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Baxdrostat in Chronic Kidney Disease (Chronic Renal Failure) Drug Details: CIN-107 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Dapagliflozin Propanediol in Diastolic Heart Failure (HFpEF)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Dapagliflozin Propanediol in Diastolic Heart Failure (HFpEF) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Dapagliflozin Propanediol in Diastolic Heart Failure (HFpEF) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MZE-829 in Chronic Kidney Disease (Chronic Renal Failure)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MZE-829 in Chronic Kidney Disease (Chronic Renal Failure) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MZE-829 in Chronic Kidney Disease (Chronic Renal Failure)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MTX-652 in Chronic Kidney Disease (Chronic Renal Failure)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MTX-652 in Chronic Kidney Disease (Chronic Renal Failure) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MTX-652 in Chronic Kidney Disease (Chronic Renal Failure)...
-
Product Insights
NewXanthine Dehydrogenase/Oxidase – Drugs In Development, 2024
The Xanthine Dehydrogenase/Oxidase pipeline drugs market research report outlays comprehensive information on the Xanthine Dehydrogenase/Oxidase targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Metabolic Disorders, Musculoskeletal Disorders, Genito Urinary System, and Central Nervous System which include indications of Hyperuricemia, Mitochondrial Diseases, Gouty Arthritis (Gout), Acute Renal Failure (ARF) (Acute Kidney Injury), Chronic Kidney Disease (Chronic Renal Failure),...
-
Product Insights
NewCytochrome P450 11B2 Mitochondrial – Drugs In Development, 2024
The Cytochrome P450 11B2 Mitochondrial pipeline drugs market research report outlays comprehensive information on the Cytochrome P450 11B2 Mitochondrial targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Cardiovascular, Genito Urinary System, Hormonal Disorders, and Metabolic Disorders which include indications of Resistant Hypertension, Hypertension, Chronic Kidney Disease (Chronic Renal Failure), Kidney Fibrosis, Primary Hyperaldosteronism, Pituitary ACTH Hypersecretion (Cushing...
-
Product Insights
NewAdenosine Receptor A3 – Drugs In Development, 2024
The Adenosine Receptor A3 pipeline drugs market research report outlays comprehensive information on the Adenosine Receptor A3 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Immunology, Gastrointestinal, Central Nervous System, and Genito Urinary System which include indications of Psoriasis, Inflammation, Metabolic Dysfunction-Associated Steatohepatitis (MASH), Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), Alzheimer's Disease, Post-Operative Pain, Kidney Fibrosis, and...
-
Product Insights
NewAngiopoietin 1 Receptor – Drugs In Development, 2024
The Angiopoietin 1 Receptor pipeline drugs market research report outlays comprehensive information on the Angiopoietin 1 Receptor targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Oncology, Ophthalmology, Infectious Disease, and Genito Urinary System which include indications of Solid Tumor, Hepatocellular Carcinoma, Diabetic Macular Edema, Wet (Neovascular / Exudative) Macular Degeneration, Unspecified Influenza Virus Infections, Coronavirus Disease 2019...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SUL-238 in Alzheimer’s Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SUL-238 in Alzheimer's Disease report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SUL-238 in Alzheimer's Disease Drug Details: SUL-238 is under development for...